on BioNxt Solutions Inc. (CVE:BNXT)
BioNxt's Strategic Move to Gen-Plus Laboratory in Munich
BioNxt Solutions Inc., a bioscience company specializing in advanced drug delivery systems, announced its transition to the Gen-Plus Contract Research and Development Organization in Munich. This move, set for March 1, 2025, aims to accelerate its R&D projects. The new facility offers a 1,000-square-meter research environment, cutting-edge technologies, and strategic collaboration opportunities within Europe's biotech hub.
BioNxt plans to utilize the state-of-the-art equipment for high-potency pharmaceutical ingredients and GMP-compliant processes. This will enhance research capabilities, promote collaborations with leading institutions, and speed up innovation timelines for its projects, including advanced drug delivery systems. CEO Hugh Rogers stated this transition marks a pivotal moment for the company, reinforcing its mission to deliver transformative therapies globally.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BioNxt Solutions Inc. news